Slide 1: Financial Statements and Related Announcement: Full Yearly Results
Financial Statements and Related Announcement::Full Yearly Results Page 1 of 1 Financial Statements and Related Announcement::Full Yearly Results Issuer & Securities Issuer/ Manager THE TRENDLINES GROUP LTD. Securities THE TRENDLINES GROUP LTD. - IL0011328858 - 42T Stapled Security No Announcement D
Slide 2: Unaudited Financial Statement and Dividend Announcement FY2015
THE TRENDLINES GROUP LTD. (Incorporated in Israel) (Company Registration No. 513970947) Unaudited Financial Statement and Dividend Announcement For the Financial Year Ended 31 December 2015 The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading
Slide 3: Income statement for full year ended 31 December 2015
PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3) AND FULL YEAR RESULTS 1(a)(i) An income statement and statement of comprehensive income, or a statement of comprehensive income (for the group) together with a comparative statement for the corresponding period of the immedia
Slide 4: Net earnings per share and notes to comprehensive income
Net earnings per share attributable to equity holders of the Company (in U.S dollars): Basic net loss (0.01) (0.01) Diluted net loss (0.01) (0.01) N.M. – Not meaningful 1(a)(ii) Notes to Consolidated Statement of Comprehensive Income 31 December 2015 31 December 2014 (Unaudited) (Audited) US$’000 US
Slide 5: Statement of financial position
1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year Group Company 31 December 31 December 31 December 31 December 2015 2014 2015 2014 (1) (Unaudited) (Audited) (Unaudited) (Unaudited) US
Slide 6: Equity and group borrowings
Receipts on account of shares, net - 1,398 - 1,398 Reserve from share-based payment transactions 4,203 2,900 4,203 2,900 Retained earnings 23,754 27,053 23,754 27,053 Total 84,124 52,855 84,124 52,855 Non-Controlling Interests 34 2,842 Total Equity 84,158 55,697 84,124 52,855 Total Liabilities and E
Slide 7: Details of collateral
Details of any collateral The Group has non-recourse debt to the Office of the Chief Scientist of the Israeli Ministry of Economy (“OCS”). These loans were extended from the OCS for the purpose of funding portfolio companies, and these loans were secured by liens on shares of the following portfolio
Slide 8: Consolidated Statement of Cash Flows
1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year. Consolidated Statement of Cash Flows Group Full Year Ended 31 December 2015 31 December 2014 (Unaudited) (Audited) US$´000 US$´000 CASH FLOW
Slide 9: Cash flows from investment and financing activities
CASH FLOWS FROM INVESTMENT ACTIVITIES: Purchase of property, plant and equipment (114) (43) Investment in bank deposits and short-term investments, net (13,622) (1,112) Proceeds from sale of short-term investments - 2,639 Investments in companies accounted for under equity method (194) - Net cash (u
Slide 10: Statement of Changes in Equity - Group
1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding fin
Slide 11: Statement of Changes in Equity - Company
Statement of Changes in Equity -- Company (Unaudited) Share Share Receipts on share Reserve from share-based Retained Total equity Capital premium account payment transactions earnings US$’000 US$’000 US$’000 US$’000 US$’000 US$’000 Balance as at 1 January 2015 100 21,404 1,398 2,900 27,053 52,855 N
Slide 12: Changes in share capital
1(d)(ii) Details of any changes in the company’s share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since
Slide 13: Total number of issued shares
Save as disclosed above, the Company did not have any treasury shares or other convertibles as at 31 December 2015 and 31 December 2014. 1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately pr
Slide 14: Earnings per share and net asset value
6. Earnings per ordinary share of the group for the current period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends Group Full Year Ended Loss per share (“LPS”) 31 December 2015 31 December 2014 (Unaudited) (
Slide 15: Review of performance of the group
8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group’s business. The review must discuss: - (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (wh
Slide 16: Income review continued
our portfolio companies as there were a lower number of portfolio companies being serviced by the Group in FY2015 as compared to FY2014. Group’s share of losses of companies accounted for under the equity method, net The Group recorded share of losses of companies accounted for under equity method,
Slide 17: Expense review
R&D expenses, net Net R&D expenses decreased by approximately US$0.4 million or 40.6% due to the decrease in R&D services provided by our Group as mentioned above, which resulted in lower expenses incurred for subcontractors and materials during FY2015. Financial expenses Financial expenses decrease
Slide 18: Consolidated Statement of Financial Position review
Consolidated Statement of Financial Position The comparative performance for the assets, liabilities and equity are based on the Group’s financial statements as at 31 December 2015 and 31 December 2014. Total assets increased by approximately 33.4% from US$81.7 million as at 31 December 2014 to US$1
Slide 19: Investments in portfolio companies
Number of Carrying Portfolio Amount Fair Value As at 31 December 2015 Companies (US$’000) (US$’000) “Investments in portfolio companies” (2) (1) 45 84,447 84,447 “Investments in companies (3) accounted for under the equity 1 – 1,329 method” Total Portfolio 46 84,447 85,776 Notes: (1) Includes a port
Slide 20: Long-term liabilities
Long-term liabilities Our total liabilities stood at approximately at US$24.8 million as at 31 December 2015. Our long-term liabilities, representing approximately 85.3% of our total liabilities decreased by approximately US$0.2 million or 0.9% from approximately US$21.4 million as at 31 December 20
Slide 21: Non-controlling interests and cash flow review
Non-controlling interests was reduced to US$34,000 at 31 December 2015 and represented an 8.3% minority held by an unrelated party in a subsidiary of the Company, Technology Incubator Misgav/Karmiel, Management Services Ltd. The reduction in the non-controlling interest was mainly due to the purchas
Slide 22: Dividend information
No dividend has been declared or recommended for the current reporting period (b)(i) Amount per share (cents) (Optional) Rate (%) Not applicable (b)(ii) Previous corresponding period (cents) (Optional) Rate (%) Not applicable. No dividend has been declared or recommended for the previous correspondi
Slide 23: Use of IPO proceeds
Follow-on investments in portfolio companies 10,000 1,240 8,760 Expansion of our operations into new markets 5,000 95 4,905 Expansion of our business units, Trendlines Labs 2,875 252 2,623 Operational expenses to support portfolio companies 1,400 - 1,400 Total 19,275 1,587 17,688 The above utilizati
Slide 24: Additional information for full year announcement
PART II – ADDITIONAL INFORMATION REQUIRED FOR FULL YEAR ANNOUNCEMENT 15. Segmented revenue and results for operating segments (of the group) in the form presented in the issuer’s most recently audited annual financial statements, with comparative information for the immediately preceding year. Not a
Slide 25: Trendlines Reports 16.2% Increase in Total Income
Creating & Developing Companies To Improve the Human Condition For Immediate Release The Trendlines Group Ltd. Reports 16.2% Increase in Total Income to US$ 9.9 Million 11.7% Increase in Portfolio Value to US$ 84.5 Million, Bottom Line Impacted by Non-Recurring, Non-Cash Pre-IPO Expenses Fair mark
Slide 26: Press release: FY2015 results
its unaudited financial results for the year ended 31 December 2015 (“FY2015”) today. This is the first financial report for the Group since its IPO on Catalist of SGX in November 2015. The fair market value of the Group’s investments in portfolio companies was US$ 84.4 million as at 31 December 201
Slide 27: Press release: management comments
that the value of our portfolio increased. Although the bottom line was impacted by the one- off, non-cash expenses related to the Pre-IPO RCL conversion discount, there was reduction in the net loss as compared to the previous year. “Given that our business model calls for significant monetary gain
Slide 28: Disclaimer
Disclaimer This release may contain statements which are subject to risks and uncertainties that could cause actual results to differ materially from such statements. You are cautioned not to place undue reliance on such statements, which are based in the current views of Management on future develo
Slide 29: Financial Highlights 2015-16
Creating & Developing Companies To Improve the Human Condition Financial Highlights 2015-16 February 2016
Slide 30: Legal Disclaimer
Legal Disclaimer IMPORTANT NOTICE This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 31: Contents
Contents I. Overview & Business Model II. Financial Highlights - Balance Sheet - Profit & Loss III. Portfolio Highlights IV. 2015-16 Highlights V. Growth Drivers 2016 and Beyond VI. Stock Information
Slide 32: I. Overview & Business Model
Ae we a +8 or Creating & developing companies to improve the human condition Medical - Agtech - Labs
Slide 33: The Trendlines Incubators: Innovation Commercialization
The Trendlines Incubators: Innovation Commercialization The Trendlines Group discovers, invests in, incubates and provide services to life science companies in the fields of medical and agricultural technologies. Israeli Government-Franchised Incubators Invest in life sciences companies Internal Inn
Slide 34: Innovation Management According to Trendlines
Innovation Management According to Trendlines 6
Slide 35: II. Financial Highlights
II. Financial Highlights Balance sheet Profit & Loss
Slide 36: Balance Sheet Summary
Balance Sheet Summary 31-Dec-15 31-Dec-14 (Unaudited) (Audited) ASSETS US$’000 US$’000 Total Current Assets 24,000 4,392 Key Financial Ratios Total Non-Current Assets 84,988 77,306 Current Assets to Current Liabilities 6.56 Total Assets 108,988 81,698 Total Assets to Total Liabilities 4.39 LIABILITI
Slide 37: Profit & Loss Summary
Profit & Loss Summary FY2015 FY2014 (Unaudited) US$’000 (Audited) US$’000 Total income 9,939 8,553 Total expenses before non-recurring, non-cash expenses related to discount on pre-IPO RCL upon IPO conversion 7,938 11,408 Total non-GAAP income before income taxes and non-recurring, non- cash expense
Slide 38: III. Portfolio Highlights
Creating & developing companies to improve the human condition ' ie Medical - Agtech - Labs
Slide 39: Growth of Portfolio Value
Growth of Portfolio Value Portfolio Values US$ 000 100000 FV of investments in consolidated non-operating subsidiaries 90000 85,776 77,494 Fair Value ("FV") of investments in companies accounted for 80000 74,639 under the equity method 70000 Portfolio Value 60000 47,499 50000 40000 29,309 30000 25,4
Slide 40: Understanding Portfolio Profit & Loss
Understanding Portfolio Profit & Loss FY2015 (Unaudited) US$’000 Gain from change in fair value of investments in Portfolio Companies 4,960 Breakdown: Undisclosed dividend 718 Increase in value to P&L - 15 companies 10,194 Decrease in value to P&L- 18 companies (5,952) Gain from change in fair value
Slide 41: Building Value Over Time
Building Value Over Time One of our 10 most valuable portfolio companies as of 31 December 2015 List of companies as at 31 December 2015; 17 written-off portfolio companies and 2 companies established before September 2007 not listed. IPO indicates reverse mergers into public companies. 13
Slide 42: Most Valuable Portfolio Companies
Most Valuable Portfolio Companies Total estimated fair market value of our 10 most valuable portfolio companies: approximately US$59.6*million, representing 69.5% of total portfolio value of approximately US$85.8*million as of 31 December 2015. Company Name Initial Investment % Owned (Fully Diluted)
Slide 43: Consistently Building Value
Consistently Building Value US$ 000 100,000 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 - 31.12.12 31.12.13 31.12.14 31.12.15 Portfolio Value Cumulative Exit Proceeds 15
Slide 44: IV. 2015-16 Highlights
Creating & developing companies to improve the human condition ' ie Medical - Agtech - Labs
Slide 45: New Companies & Incubator News
New Companies & Incubator News 5 new portfolio companies established in FY2015 September 2015: Trendlines Medical awarded tender by the Israel’s Office of the Chief Scientist to continue to operate as a technology incubator for an additional eight years. 17
Slide 46: Pre-IPO Raise & IPO
Pre-IPO Raise & IPO Memorandum of Understanding with B. Braun Melsungen AG IPO cornerstone investment from B. Braun S$7.1 million November 26, 2015 – The Trendlines Group Ltd. listed on the Catalist of the SGX 18
Slide 47: Events
Events • Building our investor base • Widening our global network with multinational corporations • Broadening our outreach to entrepreneurs 19
Slide 48: Framework Agreements
Framework Agreements 3 framework agreements with 2 medical multinational corporations and 1 agricultural multinational corporation 20
Slide 49: M&A Engagements
M&A Engagements 3 portfolio companies currently have engaged investment banks to explore M&A options ETView (TASE:ETVW), has announced that it retained a bank and has received multiple expressions of interest from potential buyers 21
Slide 50: Merger & Acquisition Transactions – Past
Merger & Acquisition Transactions – Past Estimated Year Company Description Acquirer Return (1) Trade sale; company was three 2011 PolyTouch Ltd. Covidien 6.7X years old at time of sale Trade sale; company was eight 2013 Innolap Surgical Ltd. Teleflex 3.2X months old at time of sale Trade sale; comp
Slide 51: V. Growth Drivers 2016 & Beyond
V. Growth Drivers 2016 & Beyond
Slide 52: International Incubators
International Incubators • Expanding into new markets • Exploring frameworks for new incubators • Singapore • China • Germany • Providing opportunity to scale and increase number of new companies Moshe Katzenelson joined Company in late 2015 and nominated as VP International Incubators in February 2
Slide 53: Trendlines' Competitive Strengths
Trendlines’ Competitive Strengths Strong Management Team and Track Record • Our team understands global markets and bridges cultures to build businesses • Track record to executing exit strategies for portfolio companies Extensive Network of Relationships • Quality deal flow • Strategic partnerships
Slide 54: VI. Stock Price
Creating & developing companies to improve the human condition Medical - Agtech - Labs
Slide 55: Opportunity
Opportunity SGD Last price * 0.225 IPO price 0.330 52wk high 0.395 52wk low 0.133 Market Cap 114.5 million * As of Feb 22, 2016 Shares outstanding 508.8 million Free float 365.8 million Price to Portfolio (FMV)* • Allied Minds (LSE:ALM) 2.21 • Imperial Innovations (LSE:IVO) 1.82 • IP Group (LSE:IPO)
Slide 56: Trendlines Shareholder contact
“...Trendlines is now Israel’s leading seed-stage investor in the medical device and agritech sectors.” OurCrowd, September 2013 Trendlines Shareholder 25 Feb 2016 Todd Dollinger, Chairman & CEO Steve Rhodes, Chairman & CEO www.trendlines.com todd@trendlines.com steve@trendlines.com +972.72.260.7000
Slide 57: Creating & Developing Companies To Improve the Human Condition
Creating & Developing Companies To Improve the Human Condition Todd Dollinger and Steve Rhodes Chairmen and CEOs February 2016
Slide 58: Legal Disclaimer
Legal Disclaimer IMPORTANT NOTICE This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 59: I. Overview & Business Model
Creating & developing companies to improve the human condition ' ie Medical - Agtech - Labs
Slide 60: The Trendlines Incubators: Innovation Commercialization
The Trendlines Incubators: Innovation Commercialization The Trendlines Group discovers, invests in, incubates and provide services to life science companies in the fields of medical and agricultural technologies. Israeli Government-Franchised Incubators Invest in life sciences companies Internal Inn
Slide 61: Innovation Management According to Trendlines
Innovation Management According to Trendlines 5
Slide 62: The Trendlines Group at a Glance
The Trendlines Group at a Glance 2007: Established in Israel 2 Best Incubator Awards 2015: Listed on SGX Catalist Ticker: 42T Outstanding Start-Up of the Year Early-Stage Investors in 5 Awards • Medical technologies • Agriculture and food technologies 508,741,749 shares outstanding Avg. daily volume
Slide 63: Financial Overview
Financial Overview Portfolio Value + Exit Proceeds US$ 000 100,000 90,000 80,000 70,000 60,000 50,000 Cumulative Exit Proceeds Portfolio Value 40,000 30,000 20,000 10,000 0 31.12.07 31.12.08 31.12.09 31.12.10 31.12.11 31.12.12 31.12.13 31.12.14 31.12.15 Summary P&L US$ 000 2012 2013 2014 31.12.2015
Slide 64: Consistently Building Value
Consistently Building Value US$ 000 100,000 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 - 31.12.12 31.12.13 31.12.14 31.12.15 Portfolio Value Cumulative Exit Proceeds 8
Slide 65: Innovation Management: A Unique Business Model
Innovation Management: A Unique Business Model The Trendlines Group is an early-stage investor – we start companies. • We are not a venture capital firm • No management fees • No carried interest • Cash investment + substantial in-kind investment • Deeply involved in all aspects of our companies 9
Slide 66: Sourcing Opportunities
Sourcing Opportunities ~500 deals reviewed annually Sources of Deal Flow Israel, United States; expanding to Singapore, China, and more • Entrepreneurs • Inventors • Universities and research institutions • Needs identified by industry partners Our Advantages • Successes = strong reputation in the m
Slide 67: Government Leverage Mitigates Risk
The Trendlines Group: Government Leverage Mitigates Risk Government funding leverages our capital. Israeli Government Grants • No equity to Government Israeli government typical new company grant: • No government rights to intellectual Agtech: NIS 2.125 million (~US$ 543,000) property Medical: NIS 2
Slide 68: Trendlines Labs: Our Internal Innovation Center
Trendlines Labs: Our Internal Innovation Center Strategic Partnering: 3-Stage Process Trendlines Labs’ Portfolio – Overview Field Invention Dev. Status 1. Partnerships target unmet needs Urology Reduced infection-risk Foley catheter Prototype Gloves to improve hand hygiene Infection Control complian
Slide 69: Birth to Success at High Speed
Trendlines’ Expertise: Birth to Success at High Speed Year 3 and Beyond • Path to Exit Year 2 • Governance • Follow-on funding • Follow-On Funding • Business Ideation Due Diligence Year 1 • Preclinical / clinical development • Proof of Concept trials • Commercialization • Physicians • R&D to prototy
Slide 70: II. Strengths
Creating & developing companies to improve the human condition Medical - Agtech - Labs
Slide 71: Trendlines' Strengths
Trendlines’ Strengths Strong Management Team and Track Record • Our team understands global markets and bridges cultures to build businesses • Track record to executing exit strategies for portfolio companies Extensive Network of Relationships • Quality deal flow • Strategic partnerships • Investor
Slide 72: Trendlines' Founders: Decades of Company-Building Experience
Trendlines’ Founders: Decades of Company-Building Experience 1991 Managed Israeli medical device start-up 1993 Established business development consultancy Founded The Trendlines Group 2007 Acquired two incubators Portfolio companies ETView and FlowSense go 2010 public on the Tel-Aviv Stock Exchange
Slide 73: Trendlines' Management Team
Trendlines’ Management Team: Experienced and Entrepreneurial Eran Feldhay, M.D. Nitza Kardish, Ph.D. Yosi Hazan CEO, Trendlines CEO, Trendlines CEO, Trendlines Medical Agtech Labs Former GM, Former CEO, Former GM, McKesson Israel Clal Life Sciences Biosense Webster (J&J company) Moshe Katzenelson Ga
Slide 74: Strategic Partners
Strategic Partners B. BRAUN B. BRAUN Invested S$ 7.1 million in IPO German privately held company founded 1839 Proposed Collaboration Global sales : €5.43 billion Establishing mutual deal flow 54,000 employees in 62 locations Identifying potential new investments Establishment of acceler
Slide 75: Strong Reputation and Brand
Strong Reputation and Brand • Two portfolio companies, FlowSense and ETView, taken public on the TASE • Five portfolio companies (including FlowSense) acquired by or sold assets to multinational corporations Existing Portfolio Companies* Invested in Trendlines 46 $53 Million Exits 6 Outstanding Star
Slide 76: III. Portfolio & Financial Highlights
III. Portfolio & Financial Highlights
Slide 77: Building Value Over Time
Building Value Over Time One of our 10 most valuable portfolio companies as of 31 December 2015 List of companies as at 31 December 2015; 17 written-off portfolio companies and 2 companies established before September 2007 not listed. IPO indicates reverse mergers into public companies. 21
Slide 78: Most Valuable Portfolio Companies
Most Valuable Portfolio Companies Total estimated fair market value of our 10 most valuable portfolio companies: approximately US$59.6*million, representing 69.5% of total portfolio value of approximately US$85.8*million as of 31 December 2015. Company Name Initial Investment % Owned (Fully Diluted)
Slide 79: The Trendlines Group: Exit Transactions
The Trendlines Group: Exit Transactions Estimated Year Company Description Acquirer Return (1) Trade sale; company was 2011 PolyTouch Ltd. three years old at time of Covidien 6.7X sale Trade sale; company was 2013 Innolap Surgical Ltd. eight months old at time of Teleflex 3.2X sale Trade sale; compa
Slide 80: Exit Transactions and Peer Valuation Comparables
The Trendlines Group: Exit Transactions • Jefferies Equity Research: “We value ALM on a Fair Market Value (FMV) basis.” (30 October 2014) • Four LSE-traded companies Price to Portfolio (FMV)* • Allied Minds (LSE:ALM) 2.21 • Imperial Innovations (LSE:IVO) 1.82 • IP Group (LSE:IPO) 2.96 • PureTech Hea
Slide 81: The Trendlines Group: Financial Highlights
The Trendlines Group: Financial Highlights (US$ 000) 2013 2014 2015 (audited) (audited) (unaudited) Total Portfolio Fair Value* 74,639 77,494 85,776 2012 2013 2014 2015 (audited) (audited) (audited) (unaudited) Total Income 13,768 29,707 8,553 9,939 Total Expenses before Non-recurring, Non-cash 5,15
Slide 82: Consistently Building Value
Consistently Building Value US$ 000 100,000 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 31.12.07 31.12.08 31.12.09 31.12.10 31.12.11 31.12.12 31.12.13 31.12.14 31.12.15 Portfolio Value Cumulative Exit Proceeds 26
Slide 83: Consistently Building Value
Consistently Building Value US$ 000 2,100 50 45 1,900 40 1,700 35 1,500 30 1,300 25 20 1,100 15 900 10 700 5 500 0 31.12.12 31.12.13 31.12.14 31.12.15 Average Value Per Company # of Portfolio Companies 27
Slide 84: IV. Growth Drivers & Strategy
IV. Growth Drivers & Strategy
Slide 85: Medical & Agricultural Business Drivers
Medical & Agricultural Business Drivers Health and Agriculture • Tremendous growth prospects Medical Technologies Growing global population Aging global population Growth of emerging markets: an increase in health awareness/demand for medical services Agricultural Technologies Increasing glo
Slide 86: Business Strategies and Future Plans
The Trendlines Group: Business Strategies and Future Plans Follow-on Investments in Portfolio Companies Accelerate portfolio company development Demonstrate support and confidence Limit dilution Expansion into New Markets Exploring international opportunities, including in Singapore and Chin
Slide 87: V. Selected Portfolio Companies
V. Selected Portfolio Companies
Slide 88: Improved Quality of Life for Ostomates: Stimatix GI
Trendlines’ Portfolio: Improved Quality of Life for Ostomates Stimatix GI Ideation Trendlines identified surgeon-inventor Investment & Intense Support • Active guidance in market research, business development, investment banking, governance, marketing • Trendlines recruited company CEO • Company ch
Slide 89: Natural, Nontoxic Bio-Insecticide: EdenShield
Trendlines’ Portfolio: Natural, Nontoxic Bio-Insecticide EdenShield Ideation Trendlines identified inventor Investment & Intense Support Active guidance in marketing, business development, investment banking Achievements • Independent tests show substantial reduction in insect damage in treated gree
Slide 90: Incremental Scoliosis Treatment System: ApiFix
Trendlines Portfolio Trendlines’ Portfolio: Incremental Scoliosis Treatment System ApiFix Ideation Identified serial entrepreneur-spine expert Investment & Intense Support • Company chairman is a Trendlines’ board member • Raised $3.5 million in two rounds Achievements • Completed over 65 successful
Slide 91: Water Treatment System for Aquaculture: BioFishency
Trendlines’ Portfolio: Water Treatment System for Aquaculture BioFishency Ideation Trendlines identified inventor Investment & Intense Support • Active guidance in marketing, business development, investment banking • Connected with potential partners in target markets • Prepared for investor meetin
Slide 92: Visualization of the Upper Airway: ETView
Trendlines’ Portfolio: Visualization of the Upper Airway ETView Investment & Intense Support • Trendlines’ CEO serves as company chairman • Located in Trendlines’ facilities Achievements • Sales in United States, South America, Europe, China • Public company (Tel Aviv Stock Exchange) • U.S. (FDA), E
Slide 93: Membranes for Cost-Effective Water Filtration: Advanced Mem-Tech
Trendlines’ Portfolio: Membranes for Cost-Effective Water Filtration Advanced Mem-Tech Ideation Technion-Israel Institute of Technology Investment & Intense Support • The Trendlines Group • Private investors • SEB Alliance Achievements • Commercial pilots for reverse osmosis pretreatment with Mekoro
Slide 94: VI. Stock Information
Creating & developing companies to improve the human condition ' ie Medical - Agtech - Labs
Slide 95: Opportunity
Opportunity SGD Last price * 0.225 IPO price 0.330 52wk high 0.395 52wk low 0.133 Market Cap 114.5 million * As of Feb 22, 2016 Shares outstanding 508.8 million Free float 365.8 million Price to Portfolio (FMV)* • Allied Minds (LSE:ALM) 2.21 • Imperial Innovations (LSE:IVO) 1.82 • IP Group (LSE:IPO)
Slide 96: Trendlines Shareholder contact
“...Trendlines is now Israel’s leading seed-stage investor in the medical device and agritech sectors.” OurCrowd, September 2013 Trendlines Shareholder 25 Feb 2016 Todd Dollinger, Chairman & CEO Steve Rhodes, Chairman & CEO www.trendlines.com todd@trendlines.com steve@trendlines.com +972.72.260.7000